Compare GFAI & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | KTTA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Singapore | United States |
| Employees | 1657 | 5 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 18.1M |
| IPO Year | N/A | N/A |
| Metric | GFAI | KTTA |
|---|---|---|
| Price | $0.40 | $0.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.50 | $3.00 |
| AVG Volume (30 Days) | 212.6K | ★ 570.7K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.12 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.28 |
| 52 Week High | $1.48 | $2.06 |
| Indicator | GFAI | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 33.62 |
| Support Level | $0.37 | $0.28 |
| Resistance Level | $0.42 | $0.76 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 66.39 | 12.12 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.